An Open-label, Phase II, Platform Trial Evaluating Safety and Efficacy of Multiple BI 754091 Anti-PD-1 Based Combination Regimens in PD-(L)1 naïve and PD-(L)1 Pretreated Patient Populations With Advanced and/or Metastatic Solid Tumours Who Have Had at Least One Line of Systemic Therapy
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Feb 2019
At a glance
- Drugs BI 754091 (Primary) ; BI 754111 (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 04 Feb 2019 Planned initiation date changed from 24 Jan 2019 to 12 Feb 2019.
- 21 Jan 2019 Planned initiation date changed from 17 Jan 2019 to 24 Jan 2019.
- 07 Jan 2019 Planned initiation date changed from 7 Jan 2019 to 17 Jan 2019.